Pragmatic mAb lead molecule engineering from a developability perspective
Authors:
- 29 April 2021
- journal article
- research article
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 118 (10) , 3733-3743
Abstract
As the number of antibody drugs being approved and marketed increases, our knowledge of what makes potential drug candidates a successful product has increased tremendously. One of the critical parameters that have become clear in the field is the importance of mAb “developability.” Efforts are being increasingly focused on simultaneously selecting molecules that exhibit both desirable biological potencies and manufacturability attributes. In the current study mutations to improve the developability profile of a problematic antibody that inconsistently precipitates in a batch scale‐dependent fashion using a standard platform purification process are described. Initial bioinformatic analysis showed the molecule has no obvious sequence or structural liabilities that might lead it to precipitate. Subsequent analysis of the molecule revealed the presence of two unusual positively charged mutations on the light chain at the interface of VH and VL domains, which were hypothesized to be the primary contributor to molecule precipitation during process development. To investigate this hypothesis, straightforward reversion to the germline of these residues was carried out. The resulting mutants have improved expression titers and recovered stability within a forced precipitation assay, without any change to biological activity. Given the time pressures of drug development in industry, process optimization of the lead molecule was carried out in parallel to the “retrospective” mutagenesis approach. Bespoke process optimization for large‐scale manufacturing was successful. However, we propose that such context‐dependent sequence liabilities should be included in the arsenal of in silico developability screening early in development; particularly since this specific issue can be efficiently mitigated without the requirement for extensive screening of lead molecule variants.Keywords
This publication has 43 references indexed in Scilit:
- Structure-Based Prediction of Asparagine and Aspartate Degradation Sites in Antibody Variable RegionsPLOS ONE, 2014
- Predicting the expression of recombinant monoclonal antibodies in Chinese hamster ovary cells based on sequence features of the CDR3 domainBiotechnology Progress, 2013
- Development of Scoring Functions for Antibody Sequence Assessment and OptimizationPLOS ONE, 2013
- DSF Method Optimization and Its Application in Predicting Protein Thermal Aggregation KineticsJournal of Pharmaceutical Sciences, 2013
- Application of a PEG precipitation method for solubility screening: A tool for developing high protein concentration formulationsProtein Science, 2013
- Formulation Development of Therapeutic Monoclonal Antibodies Using High-Throughput Fluorescence and Static Light Scattering Techniques: Role of Conformational and Colloidal StabilityJournal of Pharmaceutical Sciences, 2011
- High throughput thermostability screening of monoclonal antibody formulationsJournal of Pharmaceutical Sciences, 2010
- Aggregation-Prone Motifs in Human Immunoglobulin GJournal of Molecular Biology, 2009
- Downstream processing of monoclonal antibodies—Application of platform approachesJournal of Chromatography B, 2007
- Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibodyMolecular Immunology, 1993